Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Matthews

Showing results (201-210 of 293) with videos related to

Pageof 30
Sort By:
Open Forum Infectious Diseases|March 31, 2025
Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisAlice Wheeler, Jeffrey Masters, Alyssa Pradhan, et al.
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
The Medical Journal of Australia|March 6, 2022
Australian consensus recommendations for the management of hepatitis BJohn S Lubel, Simone I Strasser, Alexander J Thompson, et al.
The American Journal of Cardiology|December 31, 1997
Predictors of acute and long-term outcome with transluminal extraction atherectomy: the New Approaches to Coronary Intervention (NACI) registryM H Sketch, C J Davidson, W Yeh, et al.
Journal of Viral Hepatitis|April 17, 2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infectionM Martinello, S Bhagani, E Gane, et al.
Ebiomedicine|March 22, 2024
Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapyKasha P Singh, Anchalee Avihingsanon, Jennifer M Zerbato, et al.
Hepatology Communications|November 3, 2021
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C StudyJasmine Yee, Joanne M Carson, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Journal of Viral Hepatitis|May 18, 2022
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohortJoanne M Carson, Behzad Hajarizadeh, Josh Hanson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2011
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis CG V Matthews, S T Pham, M Hellard, et al.
Pageof 30

Showing results (201-210 of 293) with videos related to

Sort By:
Pageof 30
Open Forum Infectious Diseases|March 31, 2025
Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisAlice Wheeler, Jeffrey Masters, Alyssa Pradhan, et al.
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
The Medical Journal of Australia|March 6, 2022
Australian consensus recommendations for the management of hepatitis BJohn S Lubel, Simone I Strasser, Alexander J Thompson, et al.
The American Journal of Cardiology|December 31, 1997
Predictors of acute and long-term outcome with transluminal extraction atherectomy: the New Approaches to Coronary Intervention (NACI) registryM H Sketch, C J Davidson, W Yeh, et al.
Journal of Viral Hepatitis|April 17, 2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infectionM Martinello, S Bhagani, E Gane, et al.
Ebiomedicine|March 22, 2024
Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapyKasha P Singh, Anchalee Avihingsanon, Jennifer M Zerbato, et al.
Hepatology Communications|November 3, 2021
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C StudyJasmine Yee, Joanne M Carson, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Journal of Viral Hepatitis|May 18, 2022
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohortJoanne M Carson, Behzad Hajarizadeh, Josh Hanson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2011
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis CG V Matthews, S T Pham, M Hellard, et al.
Pageof 30